516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
H. Park(Washington University in St. Louis), Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), D. Hickman, Geoffrey I. Shapiro(Brigham and Women's Hospital), Jason S. Starr(Jacksonville College), Phillip Gallacher, Afzal Ahrorov(The University of Texas MD Anderson Cancer Center), Parminder Singh(WinnMed), Muhammad Furqan(University of Iowa), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Xīn Gào(Qingdao University), Satya Das(AstraZeneca (United States)), Amit Mahipal(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k